Abstract:Prostate-specific membrane antigen (PSMA)-based low-molecular-weight agents using beta(β)-particle-emitting radiopharmaceuticals is a new treatment paradigm for patients with metastatic castration-resistant prostate cancer. Although results have been encouraging, there is a need to improve the tumor residence time of current PSMA-based radiotherapeutics. Albumin-binding moieties have been used strategically to enhance the tumor uptake and retention of existing PSMA-based investigational agents. Previously, we developed a series of PSMA-based, β-particle-emitting, low-molecular-weight compounds. From this series, 177Lu-L1 was selected as the lead agent because of its reduced off-target radiotoxicity in preclinical studies. The ligand L1 contains a PSMA-targeting Lys-Glu urea moiety with an N-bromobenzyl substituent in the ε-amino group of Lys. Here, we structurally modified 177Lu-L1 to improve tumor targeting using two known albumin-binding moieties, 4-(p-iodophenyl) butyric acid moiety (IPBA) and ibuprofen (IBU), and evaluated the effects of linker length and composition. Six structurally related PSMA-targeting ligands (Alb-L1–Alb-L6) were synthesized based on the structure of 177Lu-L1. The ligands were assessed for in vitro binding affinity and were radiolabeled with 177Lu following standard protocols. All 177Lu-labeled analogs were studied in cell uptake and selected cell efficacy studies. In vivo pharmacokinetics were investigated by conducting tissue biodistribution studies for 177Lu-Alb-L2–177Lu-Alb-L6 (2 h, 24 h, 72 h, and 192 h) in male NSG mice bearing human PSMA+ PC3 PIP and PSMA− PC3 flu xenografts. Preliminary therapeutic ratios of the agents were estimated from the area under the curve (AUC0-192h) of the tumors, blood, and kidney uptake values. Compounds were obtained in >98% radiochemical yields and >99% purity. PSMA inhibition constants (Kis) of the ligands were in the ≤10 nM range. The long-linker-based agents, 177Lu-Alb-L4 and 177Lu-Alb-L5, displayed significantly higher tumor uptake and retention (p 4-fold higher than 177Lu-Alb-L2, 177Lu-Alb-L3, and 177Lu-Alb-L6, respectively. Also, the PSMA+ PIP tumor uptake (AUC0-192h) of 177Lu-Alb-L2 and 177Lu-Alb-L3 was ~1.5-fold higher than 177Lu-Alb-L6. However, the lowest blood AUC0-192h and kidney AUC0-192h were associated with 177Lu-Alb-L6 from the series. Consequently, 177Lu-Alb-L6 displayed the highest ratios of AUC(tumor)-to-AUC(blood) and AUC(tumor)-to-AUC(kidney) values from the series. Among the other agents, 177Lu-Alb-L4 demonstrated a nearly similar ratio of AUC(tumor)-to-AUC(blood) as 177Lu-Alb-L6. The tumor-to-blood ratio was the dose-limiting therapeutic ratio for all of the compounds. Conclusions: 177Lu-Alb-L4 and 177Lu-Alb-L6 showed high tumor uptake in PSMA+ tumors and tumor-to-blood ratios. The data suggest that linker length and composition can be modulated to generate an optimized therapeutic agent.

In Vitro and in Vivo Metabolism of Lu-AMBA, a GRP-receptor Binding Compound, and the Synthesis and Characterization of Its Metabolites.

177Lu-Amba: Synthesis and Characterization of a Selective 177Lu-Labeled GRP-R Agonist for Systemic Radiotherapy of Prostate Cancer.

A Comparative Study of Radiolabeled Bombesin Analogs for the PET Imaging of Prostate Cancer.

Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology

Pharmacokinetics and Metabolite Identification of a Novel VEGFR-2 and Src Dual Inhibitor 6-Chloro-2-methoxy-n-(2-methoxybenzyl) Acridin-9-amine in Rats by Liquid Chromatography Tandem Mass Spectrometry

Metabolism Investigation of the Peptide-Drug Conjugate LN005 in Rats Using UHPLCHRMS.

Insights into the Metabolism, Disposition, and Quantitative Profile of mGlu5 NAM AE90015 with Metabolite Identification and a Novel Integration Method

Preclinical Evaluation of a New Series of Albumin-Binding 177Lu-Labeled PSMA-Based Low-Molecular-Weight Radiotherapeutics

Metabolism and Disposition of [14C]BMS-690514 after Oral Administration to Rats, Rabbits, and Dogs.

Potential Therapeutic Radiotracers: Preparation, Biodistribution and Metabolic Characteristics of 177 Lu-labeled Cyclic RGDfK Dimer

Characterization of in Vitro Primary Metabolic Profile of Sklb-M8, A Novel Antitumor Compound, Using Liquid Chromatography Coupled with Triple Quadrupole Tandem Mass Spectrometry and Quadrupole Time-Of-Flight Tandem Mass Spectrometry

The absolute bioavailability investigation of LS177 in rats using ultra-performance liquid chromatography-tandem mass spectrometry.

Characterization of the metabolites of H3B-6545 in vitro and in vivo by using ultra-high performance liquid chromatography combined with electrospray ionization linear ion trap-orbitrap tandem mass spectrometry

177Lu–do3a–hsa–zegfr:1907: Characterization As a Potential Radiopharmaceutical for Radionuclide Therapy of EGFR-expressing Head and Neck Carcinomas

Pharmacokinetics, Mass Balance, and Metabolism of [14C]PLB1004, a Selective and Irreversible EGFR-TKI in Humans

A Heterodimeric [Rgd-Glu-[(64)cu-no2a]-6-ahx-rm2] Αvβ3/grpr-Targeting Antagonist Radiotracer for PET Imaging of Prostate Tumors.

Metabolism, Disposition and Pharmacokinetics of PR-171, a Novel Inhibitor of the 20S Proteasome.

Metabolite characterisation of the peptide–drug conjugate LN005 in liver S9s by UHPLC-Orbitrap-HRMS

Preclinical Pharmacokinetics and Biodistribution of LR004, a Novel Antiepidermal Growth Factor Receptor Monoclonal Antibody

Pharmacokinetics, Tissue Distribution and Excretion of ACT001 in Sprague-Dawley Rats and Metabolism of ACT001.

Characterization of Metabolites in Rat and Liver Microsomes after Intravenous Injection of MMAF by Liquid Chromatography/Tandem Mass Spectrometry